Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab

被引：18

作者：

Villasboas, Jose C. ^{[1
]}

Ansell, Stephen M. ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55902 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 01期

关键词：

Hodgkin lymphoma; immunotherapy; checkpoint inhibitors; PD-1; PD-L1; nivolumab; immune-related adverse events; REGULATORY T-CELLS; ADVANCED MELANOMA; EXPRESSION; BLOCKADE; INDUCE; SAFETY; PD-1; PEMBROLIZUMAB; IPILIMUMAB; EXHAUSTION;

D O I：

10.1586/14737140.2016.1121812

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab - a PD-1 inhibitor - is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.

引用

页码：5 / 12

页数：8

共 46 条

[1] Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells [J].

Ai, Weiyun Z. ;

Hou, Ling-Zhou ;

Zeiser, Robert ;

Czerwinski, Debra ;

Negrin, Robert S. ;

Levy, Ronald .

INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) :239-244

[2]

[Anonymous], N ENGL J MED

[3]

[Anonymous], OPDIVIO NIVOLUMAB PA

[4]

[Anonymous], LANCET

[5]

[Anonymous], HODGK LYMPH VERS 2 2

[6] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[7]

Asaoka Y, 2015, N ENGL J MED, V373, P1

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[10] Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant [J].

Cecchini, Michael ;

Sznol, Mario ;

Seropian, Stuart .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

← 1 2 3 4 5 →